WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering and developing potential best-in-class medicines for serious and rare ...

WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN) (the “company” or “Viridian”), a biopharmaceutical company focused on discovering and developing potential best-in-class ...

Viridian Therapeutics (NASDAQ:VRDN) reported positive topline results from the THRIVE-2 phase 3 trial of veligrotug (VRDN-001) in chronic thyroid eye disease (‘TED’) patients. The results follow the ...

Viridian Therapeutics Inc. (Nasdaq: VRDN) has signed an agreement to sell up to $50 million worth of new stock at prevailing market prices to fund its clinical research. The Boulder-based ...

Viridian Therapeutics is based out of Massachusetts. The company's main efforts are targeting both active and chronic thyroid eye disease or TED and are in late-stage development. The stock currently ...

Shares of Viridian Therapeutics Inc. VRDN fell in the extended session Monday after the biotech drug maker said it was making changes to its study design for a chronic thyroid eye disease therapy.